AVROBIO Inc.
| NASDAQ: AVRO | Healthcare / Biotechnology / USA |
| 1.53 | -0.0100 | -0.65% | Vol 237.03K | 1Y Perf 139.69% |
| Oct 2nd, 2023 16:00 DELAYED |
| BID | 1.52 | ASK | 1.58 | ||
| Open | 1.54 | Previous Close | 1.54 | ||
| Pre-Market | - | After-Market | 1.52 | ||
| - - | -0.01 -0.65% |
| Target Price | 3.20 | Analyst Rating | Strong Buy 1.25 | |
| Potential % | 109.15 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 70.80 | Earnings Rating | Strong Buy | |
| Market Cap | 68.13M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.25 | |
| Beta | 1.56 |
Today's Price Range 1.521.57 | 52W Range 0.56001.93 |
Summary:
Neutral
| Technical Indicators: | Sell |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.92% | ||
| 1 Month | -1.29% | ||
| 3 Months | 55.41% | ||
| 6 Months | 56.92% | ||
| 1 Year | 139.69% | ||
| 3 Years | -88.04% | ||
| 5 Years | -93.50% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -50.14 | |||
ROE last 12 Months | -74.80 | |||
ROA (5Y Avg) | -29.61 | |||
ROA last 12 Months | -63.06 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -67.74 | |||
Return on invested Capital Q | -18.62 | |||
Return on invested Capital Y | -14.37 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.30 | ||||
| 0.38 | ||||
| - | ||||
| - | ||||
| -0.50 | ||||
| -2.28 | ||||
| 0.38 | ||||
| 2.24 | ||||
| -63 563 800.00 | ||||
| Forward PE | -3.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.30 | ||||
| 7.80 | ||||
| 0.13 | ||||
| 0.16 | ||||
| - | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | 1.35 | -0.37 | -127.41 |
| Q01 2023 | -0.56 | -0.57 | -1.79 |
| Q04 2022 | -0.32 | -0.57 | -78.12 |
| Q03 2022 | -0.50 | -0.52 | -4.00 |
| Q02 2022 | -0.54 | -0.64 | -18.52 |
| Q01 2022 | -0.58 | -0.68 | -17.24 |
| Q04 2021 | -0.71 | -0.65 | 8.45 |
| Q03 2021 | -0.74 | -0.75 | -1.35 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.23 | 58.18 | Positive |
| 12/2023 QR | -0.12 | 78.18 | Positive |
| 12/2023 FY | 0.58 | 205.46 | Positive |
| 12/2024 FY | -0.48 | 70.37 | Positive |
| Next Report Date | 14th Nov 2023 |
| Estimated EPS Next Report | -0.23 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 237.03K |
| Shares Outstanding | 44.53K |
| Shares Float | 29.54M |
| Trades Count | 1.16K |
| Dollar Volume | 364.25K |
| Avg. Volume | 517.74K |
| Avg. Weekly Volume | 202.97K |
| Avg. Monthly Volume | 324.75K |
| Avg. Quarterly Volume | 1.03M |
AVROBIO Inc. (NASDAQ: AVRO) stock closed at 1.53 per share at the end of the most recent trading day (a -0.65% change compared to the prior day closing price) with a volume of 237.03K shares and market capitalization of 68.13M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 123 people. AVROBIO Inc. CEO is Geoff Mackay.
The one-year performance of AVROBIO Inc. stock is 139.69%, while year-to-date (YTD) performance is 114.62%. AVRO stock has a five-year performance of -93.5%. Its 52-week range is between 0.56 and 1.93, which gives AVRO stock a 52-week price range ratio of 70.80%
AVROBIO Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 0.38, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -63.06%, a ROC of -67.74% and a ROE of -74.80%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AVROBIO Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. AVROBIO Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for AVROBIO Inc. is Strong Buy (1.25), with a target price of $3.2, which is +109.15% compared to the current price. The earnings rating for AVROBIO Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AVROBIO Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AVROBIO Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.72, ATR14 : 0.06, CCI20 : -63.58, Chaikin Money Flow : -0.06, MACD : 0.00, Money Flow Index : 34.15, ROC : -3.77, RSI : 48.55, STOCH (14,3) : 25.00, STOCH RSI : 0.18, UO : 40.31, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AVROBIO Inc. in the last 12-months were: Geoff Mackay (Option Excercise at a value of $100 539), Geoffrey Mackay (Option Excercise at a value of $41 859)
AVROBIO Inc.
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.
CEO: Geoff Mackay
Telephone: +1 617 914-8420
Address: One Kendall Square, Cambridge 02139, MA, US
Number of employees: 123
